BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.
By María E. Reig1 , 2, Alejandro Forner1 , 2, J. Rimola, J. Ferrer-Fábrega, M. Burrel, Á. García-Criado, R. Kelley, Peter R. Galle, V. Mazzaferro, R. Salem and 6 more. Journal of Hepatology, 2021
2,982 citations recorded by the source corpus.
Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need of further research to gain their incorporation into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that is needed to take clinical decisions in individual patients so that the recommendation takes into account all the needed parameters to allow a personalised approach.
Subfields: Hepatology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f62ac06907a7ba4dd7789ecdfa41ae29e9296773
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Oncology
Citations in the corpus
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, methodology): “Nevertheless, specific treatment decisions for individual patients are best made by mutidisciplinary teams of providers (for example, transplant hepatologists, surgeons, interventional radiologists and medical oncologists), nurses and patient navigators 91,167,168 .”